CNM-Au8 is an oral suspension of gold nanocrystals designed to act as a biocatalyst, improving cellular energy metabolism and resilience. It supports key metabolic cofactors like NAD+ and enhances mitochondrial efficiency, thereby addressing core mechanisms of cellular aging and neurodegeneration. Its primary relevance to healthspan is its potential to restore energetic function and protect cells from age-related decline.
Verdict
A promising neuroprotective agent, but highly experimental for any healthspan application.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
C
MONTHLY COST
$0 - $0
Protocol
- Clinical trials have investigated oral daily doses ranging from 15mg to 60mg.
Flags
- Currently an investigational drug not approved by the FDA for any indication.
- Not available for public purchase; accessible only through clinical trials.
- All human data is in patients with severe neurodegenerative diseases (ALS, MS, Parkinson's).
- Long-term effects of systemic gold nanoparticle exposure in healthy humans are unknown.